Emmaus Life Sciences Price to Free Cash Flow Ratio 2006-2021 | EMMA

Historical price to free cash flow ratio values for Emmaus Life Sciences (EMMA) since 2006. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Emmaus Life Sciences Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2019-09-10 2.77 0.00
2019-09-30 2.77 $-1.35 0.00
2019-06-30 7.80 $-0.11 0.00
2019-03-31 8.28 $5.17 1.60
2018-12-31 4.39 $-1.39 0.00
2018-09-30 9.48 $-3.55 0.00
2018-06-30 10.92 $-4.73 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.080B $0.023B
Emmaus Life Sciences Inc. is a commercial-stage biopharmaceutical company. It is engaged in the discovery, development, marketing and sale of treatments and therapies, for rare and orphan disease categories. Emmaus Life Sciences Inc., formerly known MYnd Analytics Inc., is based in Torrance, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00